Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80684 |
Name | diffuse midline glioma, H3 K27M-mutant |
Definition | A histone mutated tumor that is characterized by the presence of histone H3 K27M mutation located throughout the midline structures of the central nervous system. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma histone mutated tumor diffuse midline glioma, H3 K27M-mutant |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04655404 | Phase I | Larotrectinib | A Pilot Study of Larotectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion (CONNECT1903) | Recruiting | USA | DEU | CAN | 3 |
NCT04732065 | Phase I | ONC206 | ONC206 for Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors (PNOC 023) | Recruiting | USA | 1 |
NCT04804709 | Phase I | Panobinostat | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | Active, not recruiting | USA | 0 |
NCT04808245 | Phase I | Atezolizumab + H3K27M peptide vaccine + Imiquimod | A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (INTERCEPT-H3) | Recruiting | DEU | 0 |
NCT04870944 | Phase Ib/II | CBL0137 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Active, not recruiting | USA | 0 |
NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Recruiting | USA | 0 |
NCT04943848 | Phase I | rHSC-DIPGVax Balstilimab + rHSC-DIPGVax Balstilimab + rHSC-DIPGVax + Zalifrelimab | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | Recruiting | USA | 0 |
NCT04978727 | Phase I | SurVaxM | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Recruiting | USA | 0 |
NCT05009992 | Phase II | GDC-0084 + ONC201 ONC201 + Panobinostat | Combination Therapy for the Treatment of Diffuse Midline Gliomas | Recruiting | USA | 4 |
NCT05081180 | Phase I | Avelumab + Lenvatinib | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | Recruiting | USA | FRA | DEU | CAN | 1 |
NCT05099003 | Phase Ib/II | Selinexor | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Recruiting | USA | 0 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Recruiting | ESP | DEU | 1 |
NCT05476939 | Phase III | Everolimus ONC201 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (BIOMEDE 2) | Recruiting | FRA | 0 |
NCT05518838 | Expanded access | OKN-007 | Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered | Available | USA | 0 |
NCT05580562 | Phase III | ONC201 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION) | Recruiting | USA | 0 |